SFERA Archivio dei prodotti della Ricerca dell'Università di Ferrara

SECCHIERO, Paola
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 26.536
AS - Asia 13.074
EU - Europa 7.402
SA - Sud America 2.192
AF - Africa 315
OC - Oceania 28
Continente sconosciuto - Info sul continente non disponibili 5
AN - Antartide 1
Totale 49.553
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 26.072
SG - Singapore 5.033
CN - Cina 3.222
IT - Italia 1.748
BR - Brasile 1.740
VN - Vietnam 1.484
DE - Germania 1.123
HK - Hong Kong 1.068
UA - Ucraina 1.067
GB - Regno Unito 763
TR - Turchia 740
PL - Polonia 675
FI - Finlandia 473
FR - Francia 412
RU - Federazione Russa 346
JP - Giappone 294
SE - Svezia 281
IN - India 261
ID - Indonesia 228
CA - Canada 220
AR - Argentina 179
MX - Messico 178
BD - Bangladesh 157
ZA - Sudafrica 129
NL - Olanda 102
IQ - Iraq 99
ES - Italia 91
PK - Pakistan 73
EC - Ecuador 64
BE - Belgio 57
VE - Venezuela 55
CO - Colombia 53
UZ - Uzbekistan 52
SA - Arabia Saudita 51
LT - Lituania 41
CZ - Repubblica Ceca 39
MA - Marocco 37
MY - Malesia 35
AT - Austria 32
CL - Cile 32
EG - Egitto 32
PH - Filippine 27
TN - Tunisia 26
AU - Australia 24
PY - Paraguay 24
AE - Emirati Arabi Uniti 23
DZ - Algeria 22
JO - Giordania 20
KE - Kenya 20
KR - Corea 20
IR - Iran 19
TW - Taiwan 18
UY - Uruguay 17
AZ - Azerbaigian 16
BO - Bolivia 16
EE - Estonia 15
IL - Israele 15
RO - Romania 15
IE - Irlanda 14
KG - Kirghizistan 14
OM - Oman 14
LK - Sri Lanka 13
NP - Nepal 13
CH - Svizzera 12
CR - Costa Rica 12
JM - Giamaica 12
PT - Portogallo 12
TH - Thailandia 11
BG - Bulgaria 10
DO - Repubblica Dominicana 10
GR - Grecia 10
PS - Palestinian Territory 10
RS - Serbia 10
ET - Etiopia 9
PE - Perù 9
HN - Honduras 8
KZ - Kazakistan 8
SN - Senegal 8
AL - Albania 7
CI - Costa d'Avorio 7
LB - Libano 7
DK - Danimarca 6
GE - Georgia 6
NI - Nicaragua 6
SK - Slovacchia (Repubblica Slovacca) 6
HR - Croazia 5
CY - Cipro 4
LV - Lettonia 4
LY - Libia 4
MD - Moldavia 4
PA - Panama 4
TG - Togo 4
BN - Brunei Darussalam 3
GT - Guatemala 3
HU - Ungheria 3
KW - Kuwait 3
MK - Macedonia 3
SI - Slovenia 3
SR - Suriname 3
TT - Trinidad e Tobago 3
Totale 49.492
Salva come PNG Salva come JPEG
Città #
Ashburn 3.196
Singapore 3.108
Fairfield 2.805
Woodbridge 2.506
Houston 1.641
San Jose 1.331
Jacksonville 1.169
Seattle 1.138
Chandler 1.099
Ann Arbor 1.062
Hong Kong 1.049
Wilmington 992
Santa Clara 982
Beijing 974
Cambridge 956
Warsaw 660
Ferrara 611
Dallas 504
Ho Chi Minh City 483
Los Angeles 435
Izmir 371
Hanoi 342
Nanjing 339
Council Bluffs 306
New York 306
Princeton 280
Tokyo 277
Lauterbourg 254
Munich 236
Boardman 232
San Diego 214
Milan 202
São Paulo 179
Helsinki 166
Jakarta 166
Shanghai 151
Orem 121
Buffalo 110
London 109
Mexico City 109
Nanchang 108
Shenyang 105
Dearborn 98
Chicago 96
Bologna 94
Tianjin 91
Denver 81
Montreal 80
Chennai 79
The Dalles 78
Hefei 76
Turku 73
Brooklyn 72
Da Nang 72
Falls Church 70
Frankfurt am Main 70
Johannesburg 70
Changsha 65
Atlanta 62
Hebei 59
Moscow 57
Dong Ket 56
Poplar 56
Brussels 55
Jiaxing 55
Toronto 55
Mountain View 54
Haiphong 53
San Francisco 53
Stockholm 52
Columbus 48
Bremen 47
Manchester 45
Boston 43
Tashkent 42
Zhengzhou 42
Rio de Janeiro 41
San Mateo 41
Baghdad 39
Kunming 39
Norwalk 39
Jinan 38
Rome 38
Redwood City 37
Auburn Hills 35
Phoenix 35
Guangzhou 34
Mumbai 34
Hải Dương 33
Tappahannock 32
Verona 31
Ankara 30
Matera 30
Istanbul 29
Nuremberg 29
Brasília 28
Porto Alegre 28
Brno 27
Falkenstein 27
Addison 26
Totale 34.383
Salva come PNG Salva come JPEG
Nome #
Design, synthesis and biological characterization of novel mitochondria targeted dichloroacetate-loaded compounds with antileukemic activity 324
Anti-leukemic activity of microRNA-26a in a chronic lymphocytic leukemia mouse model 297
Gene-gene interactions among coding genes of iron-homeostasis proteins and APOE-alleles in Cognitive Impairment Diseases 283
The anti-leukemic activity of sodium dichloroacetate in p53(mutated/null) cells is mediated by a p53-independent ILF3/p21 pathway 272
Intranasal Administration of Recombinant TRAIL Down-Regulates CXCL-1/KC in an Ovalbumin-Induced Airway Inflammation Murine Model 271
Sodium dichloroacetate exhibits anti-leukemic activity in B-chronic lymphocytic leukemia (B-CLL) and synergizes with the p53 activator Nutlin-3 271
Cell cycle block by p53 acrivation reduces SARS-COV-2 release in infected alveolar basal epithelial A549-hACE2 cells 265
Expeditious Synthesis and Biological Characterization of Enantio-Enriched (-)-Nutlin-3 265
Anticancer Activity of Aqueous Extracts from Asparagus officinalis L. Byproduct on Breast Cancer Cells 265
Cell cycle block by p53 activation reduces SARS-CoV-2 release in infected alveolar basal epithelial A549-hACE2 cells 264
MDM2/X inhibitors under clinical evaluation: Perspectives for the management of hematological malignancies and pediatric cancer 264
Serum From Advanced Heart Failure Patients Promotes Angiogenic Sprouting and Affects the Notch Pathway in Human Endothelial Cells 257
A set of NF-κB-regulated microRNAs induces acquired TRAIL resistance in Lung cancer 253
Ibrutinib synergizes with MDM-2 inhibitors in promoting cytotoxicity in B chronic lymphocytic leukemia 250
Antiangiogenic activity of the MDM2 antagonist nutlin-3 248
Nutlin-3 up-regulates the expression of Notch1 in both myeloid and lymphoid leukemic cells, as part of a negative feedback antiapoptotic mechanism 247
Conjunctival sac fluid contains elevated levels of soluble TRAIL: implications for the anti-tumoral surveillance of the anterior surface of the eye 246
COVID-19 and individual genetic susceptibility/receptivity: Role of ACE1/ACE2 genes, immunity, inflammation and coagulation. might the double x-chromosome in females be protective against SARS-COV-2 compared to the single x-chromosome in males? 246
Association between thyroid hormones and TRAIL 245
Synergistic cytotoxic activity of recombinant TRAIL plus the non-genotoxic activator of the p53 pathway nutlin-3 in acute myeloid leukemia cells 244
CCR4+ skin-tropic phenotype as a feature of central memory CD8+ T cells in healthy subjects and psoriasis patients 240
Characterization of human herpesvirus 6 strains isolated from patients with exanthem subitum with or without cutaneous rash 239
Association of serum tumor necrosis factor-related apoptosis inducing ligand with body fat distribution as assessed by dual X-rays absorptiometry 237
Association of tumor necrosis factor-related apoptosis-inducing ligand with total and cardiovascular mortality in older adults 237
Actively targeted nanocarriers for drug delivery to cancer cells 237
HelixComplex snail mucus exhibits pro-survival, proliferative and pro-migration effects on mammalian fibroblasts 236
Coagulation Factor XII Levels and Intrinsic Thrombin Generation in Multiple Sclerosis 234
Serum Soluble Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Levels in Older Subjects with Dementia and Mild Cognitive Impairment 233
Multiple dye-doped NIR-emitting silica nanoparticles for both flow cytometry and in vivo imaging 229
Differential gene expression induction by TRAIL in B chronic lymphocytic leukemia (B-CLL) cells showing high versus low levels of Zap-70 227
Metformin combined with sodium dichloroacetate promotes B leukemic cell death by suppressing anti-apoptotic protein Mcl-1 226
Elevated levels of TRAIL in systemic lupus erythematosus are associated to the presence of anti-SSA/SSB antibodies 225
The circulating levels of TRAIL are extremely low after delivery but rapidly recover in both mothers and newborns 225
TRAIL and Ceruloplasmin Inverse Correlation as a Representative Crosstalk between Inflammation and Oxidative Stress 224
Evidence for a role of TNF-related apoptosis-inducing ligand (TRAIL) in the anemia of myelodysplastic syndromes 223
GM-CSF Exhibits Anti-Inflammatory Activity on Endothelial Cells Derived from Chronic Venous Disease Patients 223
The p53 transcriptional pathway is preserved in ATMmutated and NOTCH1mutated chronic lymphocytic leukemias 223
TNF-related apoptosis inducing ligand in ocular cancers and ocular diabetic complications 223
Upregulation of the alternative splicing factor NOVA2 in colorectal cancer vasculature 223
The MDM-2 antagonist nutlin-3 promotes the maturation of acute myeloid leukemic blasts 221
Anti-leukemic activity of Dasatinib in both p53 wild-type and p53 mutated B malignant cells 221
Clinical perspectives of TRAIL: Insights into central nervous system disorders 220
Characterization Methods for Nanoparticle–Skin Interactions: An Overview 218
Human bone marrow mesenchymal stem cells display anti-cancer activity in SCID mice bearing disseminated non-hodgkin's lymphoma xenografts 215
Association of Soluble Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL) with Central Adiposity and Low-Density Lipoprotein Cholesterol 215
TRAIL promotes the survival, migration and proliferation of vascular smooth muscle cells 214
Cyclooxygenase-2 expression is induced during human megakaryopoiesis and characterizes newly formed platelets 213
The 85-kilodalton phosphoprotein (pp85) of human herpesvirus 7 is encoded by open reading frame U14 and localizes to a tegument substructure in virion particles 212
Kinetic Profiles of Inflammatory Mediators in the Conjunctival Sac Fluid of Patients upon Photorefractive Keratectomy 212
Nanoparticles Loaded with Nutlin-3 Display Cytotoxicity Towards p53(wild-type) JVM-2 But Not Towards p53(mutated) BJAB Leukemic Cells 211
Context-dependent function of ROS in the vascular endothelium: The role of the Notch pathway and shear stress 210
Human Herpesvirus 7 infection induces profound cell cycle perturbations coupled to disregulation of cdc2 and cyclin B and polyploidization of CD4+ T Cells 208
Activated human NK and CD8+ T cells express both TNF-related apoptosis-inducing ligand (TRAIL) and TRAIL receptors but are resistant to TRAIL-mediated cytotoxicity 207
Functional integrity of the p53-mediated apoptotic pathway induced by the nongenotoxic agent nutlin-3 in B-cell chronic lymphocytic leukemia (B-CLL) 207
Applications of nanoparticles in cancer medicine and beyond: optical and multimodal in vivo imaging, tissue targeting and drug delivery 207
Redox signaling and oxidative stress: Cross talk with TNF-related apoptosis inducing ligand activity 207
Is there any role for tumour necrosis factor related apoptosis inducing ligand–osteoprotegerin (TRAIL–OPG) interaction in rheumatoid arthritis? 206
HIV-1 Tat-mediated inhibition of the tyrosine hydroxylase gene expression in dopaminergic neuronal cells 206
TRAIL counteracts the proadhesive activity of inflammatory cytokines in endothelial cells by down-modulating CCL8 and CXCL10 chemokine expression and release 205
Hydrogen sulfide down-regulates the expression and release of osteoprotegerin (OPG) by vascular endothelial cells 204
The effectiveness of Robot-Assisted Gait Training versus conventional therapy on mobility in severely disabled progressIve MultiplE sclerosis patients (RAGTIME): Study protocol for a randomized controlled trial 204
In vivo anti-lymphoma activity of an agonistic human recombinant anti-TRAIL-R2 minibody. 202
The Sorafenib plus Nutlin-3 combination promotes synergistic cytotoxicity in acute myeloid leukemic cells irrespectively of the FLT3 and p53 status 202
MDM2 antagonist Nutlin-3 suppresses the proliferation and differentiation of human pre-osteoclasts through a p53-dependent pathway 200
HIV-1 Tat protein down-regulates CREB transcription factor expression in PC12 neuronal cells through a phosphatidylinositol 3-kinase/AKT/cyclic nucleoside phosphodiesterase pathway 200
Circulating levels of frizzled-related protein (FRZB) are increased in patients with early rheumatoid arthritis and decrease in response to disease-modifying antirheumatic drugs. 200
Combined treatment of CpG-oligodeoxynucleotide with Nutlin-3 induces strong immune stimulation coupled to cytotoxicity in B-chronic lymphocytic leukemic (B-CLL) cells 200
Circulating TRAIL shows a significant post-partum decline associated to stressful conditions 199
Involvement of TRAIL/TRAIL-receptors in human intestinal cell differentiation 198
Eosinophils and purinergic signaling in health and disease 198
In Vitro Characterization of Circulating Endothelial Progenitor Cells Isolated from Patients with Acute Coronary Syndrome 197
Relationship between low levels of circulating TRAIL and atheromatosis progression in patients with chronic kidney disease 197
MicroRNA-148a reduces tumorigenesis and increases TRAIL-induced apoptosis in NSCLC 196
Proper design of silica nanoparticles combines high brightness, lack of cytotoxicity and efficient cell endocytosis 195
A novel endovenous scaffold for the treatment of chronic venous obstruction in a porcine model: Histological and ultrastructural assessment 194
Multimodal near-infrared-emitting PluS Silica nanoparticles with fluorescent, photoacoustic, and photothermal capabilities 193
Molecular targets for selective killing of TRAIL-resistant leukemic cells. 191
Plasma levels of soluble NCAM in multiple sclerosis 190
Anti-Inflammatory and Cortical Responses after Transcranial Direct Current Stimulation in Disorders of Consciousness: An Exploratory Study 189
Engagement of CD28 modulates CXC chemokine receptor 4 surface expression in both resting and CD3-stimulated CD4+ T cells 188
Mesenchymal stem cells display hepato-protective activity in lymphoma bearing xenografts 188
Tumor necrosis factor-related apoptosis-inducing ligand promotes migration of human bone marrow multipotent stromal cells 187
Release of a specific set of proinflammatory adipokines by differentiating 3T3-L1 cells 187
Association of human herpes virus 6 (HHV-6) with multiple sclerosis: Increased IgM response to HHV-6 early antigen and detection of serum HHV-6 DNA 187
Chemoresistive Nanostructured Sensors for Tumor Pre-Screening 185
Endothelial PDGF-BB produced ex vivo correlates with relevant hemodynamic parameters in patients affected by chronic venous disease 184
Effects of hypoxia and bed rest on markers of cardiometabolic risk: Compensatory changes in circulating trail and glutathione redox capacity 184
The MDM2 inhibitor Nutlin-3 attenuates streptozotocin-induced diabetes mellitus and increases serum level of IL-12p40. 183
Activation of the p53 pathway down-regulates the osteoprotegerin expression and release by vascular endothelial cells 182
Pivotal role of cyclic nucleoside phosphodiesterase 4 in Tat-mediated CD4+ T cell hyperactivation and HIV type 1 replication 181
TRAIL inhibits osteoclastic differentiation by counteracting RANKL-dependent p27Kip1 accumulation in pre-osteoclast precursors 181
Circulating levels of TNF-related apoptosis inducing-ligand are decreased in patients with large adult-type granulosa cell tumors—implications for therapeutic potential 180
Osteoprotegerin induces morphological and functional alterations in mouse pancreatic islets. 178
SARS-CoV-2 nucleocapsid-protein and ultrastructural modifications in small bowel of a four week negative COVID-19 patient 178
State of art and recent developments of anti-cancer strategies based on TRAIL 177
Activation of the nitric oxide synthase pathway represents a key component of the TNF-related apoptosis-inducing ligand (TRAIL)-mediated cytotoxicity on hematological malignancies. 176
Role of the RANKL/RANK system in the induction of interleukin-8 (IL-8) in B chronic lymphocytic leukemia (B-CLL) cells 175
Autoinflammatory diseases and cytokine storms-imbalances of innate and adaptative immunity 174
Pegylated TRAIL retains anti-leukemic cytotoxicity and exhibits improved signal transduction activity with respect to TRAIL 173
Low Circulating TRAIL Levels Are Associated with Increase of Resistin and Lipocalin-2/ngal Adipokines in Postmenopausal Women 173
Totale 21.626
Salva come PNG Salva come JPEG
Categoria #
all - tutte 209.328
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 209.328
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211.416 0 0 0 0 0 0 0 0 0 671 469 276
2021/20222.870 87 314 220 115 161 164 175 165 101 233 334 801
2022/20232.687 296 131 95 311 408 394 116 245 358 48 160 125
2023/20241.451 162 182 53 38 105 201 45 148 30 30 59 398
2024/20256.733 214 192 533 310 851 515 285 389 1.154 632 957 701
2025/202618.060 1.835 862 1.785 2.370 2.681 1.349 2.226 1.093 1.917 1.942 0 0
Totale 50.128